BJP Try Advances in Psychiatric Treatment Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michelson, D.
Right arrow Articles by Tollefson, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michelson, D.
Right arrow Articles by Tollefson, G.

The British Journal of Psychiatry 174: 213-218 (1999)
© 1999 The Royal College of Psychiatrists

Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group

D Michelson, M Pollack, RB Lydiard, R Tamura, R Tepner and G Tollefson
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianpolis, IN 46285, USA.

BACKGROUND: Data concerning appropriate treatment in panic disorder following an initial response to acute therapy are limited. AIMS: To assess the safety and efficacy of continued fluoxetine treatment following successful acute therapy of panic disorder. METHOD: Patients who responded to acute fluoxetine treatment were randomised to 24 weeks of continued fluoxetine or placebo. RESULTS: Fluoxetine responders randomised to continue on their acute-phase fluoxetine dose experienced statistically significant improvement in panic attack frequency and phobia rating scale score over 24 weeks of therapy, while those switched to placebo experienced statistically significant worsening in Hamilton Anxiety (HAM-A), Hamilton Depression (HAM-D) and SCL-90-R rating scores. CONCLUSIONS: Fluoxetine was associated with improved clinical outcomes compared with placebo during continuation therapy.


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
J Psychopharmacol, November 1, 2005; 19(6): 567 - 596.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
F. MARTENYI, E. B. BROWN, H. ZHANG, S. C. KOKE, and A. PRAKASH
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
The British Journal of Psychiatry, October 1, 2002; 181(4): 315 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
A. Scott, A. Davidson, and K. Palmer
Antidepressant drugs in the treatment of anxiety disorders
Advan. Psychiatr. Treat., July 1, 2001; 7(4): 275 - 282.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. R. Mavissakalian and J. M. Perel
Long-term Maintenance and Discontinuation of Imipramine Therapy in Panic Disorder With Agoraphobia
Arch Gen Psychiatry, September 1, 1999; 56(9): 821 - 827.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1999 The Royal College of Psychiatrists.